Journal of The Korean Ophthalmological Society (대한안과학회지)

The Korean Ophthalmological Society (대한안과학회)
권호 표지

Follow-Up Changes of Multifocal Electroretinogram in a Patient with Vogt-Koyanaki-Harada Syndrome

보크트-고야나기-하라다 증후군 환자 1예에서 치유 경과에 따른 다국소망막전위도 변화

Lim, Sang Hyun;Park, Su-Eun;Park, Tae Kwann;Ohn, Young Hoon
임상현;박수은;박태관;온영훈

  • Published : 20060000
⟨ Previous Next ⟩

Abstract

Purpose: To assess the changes of retinal function together with recovery progress in a patient with Vogt-Koyanaki-Harada syndrome using a multifocal electroretinogram (mfERG). Methods: The retinal changes of a 32-year-old woman diagnosed with Vogt-Koyanaki-Harada syndrome have been investigated and compared for different times such as before treatment and 3 and 6 months after treatment using a fluorescein angiogram, electroretinogram (ERG) and mfERG. Results: As time passed, the patient`s visual acuity was recovered, the serous retinal detachment in the posterior pole was restored, and the phenomenon of late subretinal leakage disappeared on fluorescein angiogram, while aggregation and atrophy of the retinal pigment epithelium were detected. The early-stage responses of the retina decreased on ERG; however, it has gradually recovered and was determined to be normal after 6 months. Responses measured on the mfERG have increased during the 6 months after surgery compared to the pre-treatment, but there was still a partial lack of response. Conclusions: In this case, the abnormal condition of retinal function existed continuously on the mfERG, even when the serous retinal detachment in the posterior pole was recovered. In this regard, a long-term systematic investigation and subsequent mfERG treatment have been thought to be necessary for patients with this disease.

목적 : 보크트-고야나기-하라다 증후군(Vogt-Koyanaki-Harada syndrome) 환자 1예에서 치유경과에 따른 망막기능의 변화를 다국소 망막전위도를 이용하여 알아보고자 하였다. 대상과 방법 : 보크트-고야나기-하라다 증후군으로 진단받은 32세 여성에서 치료 전, 치료 3개월, 치료 6개월의 망막변화를 형광안저혈관조영, 망막전위도, 다국소 망막전위도를 이용하여 비교하였다. 결과 : 시간이 지남에 따라 시력이 회복되었으며 후극부의 장액성 망막박리가 회복되면서 형광안저혈관조영에서 후기 망막하누출이 소실되었고 망막색소상피의 응집 및 위축을 보였다. 망막전위도에서는 초기에 반응이 감소하였으나 점차로 회복되어 6개월째 정상 수준의 반응을 보였다. 다국소 망막전위도는 치료 전에 비해서 치료 6개월 후 반응이 증가되었으나 여전히 국소적으로 반응 결핍이 관찰되었다. 결론 : 본 환자로 미루어 보아 후극부의 장액성 망막박리가 회복되어도 망막기능의 이상은 지속되는 것을 다국소 망막전위도를 통해 알 수 있었으며 이 질환의 환자들에 대해서 다국소 망막전위도의 장기간 체계적인 검사가 필요하고 이에 따른 적절한 치료가 필요할 것으로 생각된다.

Keywords

References

  1. Nussenblatt RB. Vogt-Koyanaki-Harada syndrome. In : Ryan SJ, ed. Retina, 3rd ed. St. Louis, Mosby, 2001; v. 2. Chap. 109
  2. Smith RE, Nozik RA. Vogt-Koyanagi-Harada syndrome, Uveitis. Baltimore: Wiliams & Wilkins, 1989;162-5
  3. Lertsumitkul S, Whitcup SM, Nusssenblatt RB, Chan CC. Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Graefe's Arch Clin Exp Ophthalmol 1999;237:1039-45 https://doi.org/10.1007/s004170050342
  4. Sutter EE, Tran D. The field topography of ERG components in man: 1. The photopic luminance response. Vision Res 1992;32:433-46 https://doi.org/10.1016/0042-6989(92)90235-B
  5. Ohn YH, Ahn YS. Clinical Applications of Multifocal Electroretinography (mfERG). J Korean Ophthalmol Soc 2002;43:1901-17
  6. Greenstein VC, Chen H, Hood DC, et al. The Nature and Extent of Retinal Dysfunction associated with Diabetic Macular Edema. Invest Ophthalmol Vis Sci 2000;41:3643-53
  7. Palmowski AM, Aligayer R, Heinemann-Vernaleken B, et al. Influence of Photodynamic Therapy In Choroidal Neovascularization on Focal Retinal Function Assessed with theMultifocal Electroretinogram and Perimetry. Ophthalmology 2002;109:1788-92 https://doi.org/10.1016/S0161-6420(02)01147-8
  8. Lee Yl, Ohn YH, Shin HH. Normal Values of Standard Electroretinography, and Change with Age and Sex (I). J Korean Ophthalmol Soc 1996;37:1813-21
  9. Perry HD, Font RL. Clinical and Histologic observations in severe Vogt-Koyanagi-Harada Syndrome. Am J Ophthalmol 1977;83:242-54 https://doi.org/10.1016/0002-9394(77)90623-7
  10. Bruno MG, McPherson SD. Harada's disease. Am J Ophthalmol 1949;32:513 https://doi.org/10.1016/0002-9394(49)90876-4
  11. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995;39:265-92 https://doi.org/10.1016/S0039-6257(05)80105-5
  12. Cunningham ET. Vogt-Koyanagi-Harada syndrome in a 4-year-old child. Am J Ophthalmol 1995;120:675-7 https://doi.org/10.1016/S0002-9394(14)72219-6
  13. Read RW, Rao NA, Cunningham ET. Vogt-Koyanagi-Harada disease. Current Opinion in Ophthalmology 2000;11:437-42 https://doi.org/10.1097/00055735-200012000-00009
  14. Sugiura S. Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 1978;22:9-35
  15. Choi DG, Chung H. Clinical Analysis of Uveitis in Korea. J Korean Ophthalmol 1989;30:543-52
  16. Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1980;90:69-75 https://doi.org/10.1016/S0002-9394(14)75078-0
  17. Sakamoto T, Murata T, Inomata H. Class II major histocompatibility complex on melanocytes of Vogt-KoyanagiHarada disease. Arch Ophthalmol 1991;109:1270-4 https://doi.org/10.1001/archopht.1991.01080090096030
  18. Woo KI, Chung H. Clinical Analysis of Vogt-Koyanagi-Harada Disease. J Korean Ophthalmol Soc 1993;34:26-34
  19. Harada T, Sugita K, Saito A, Awaya S. Treatment of severe uveitis with cyclosporin A. Ophthalmologica 1987;195:21-5 https://doi.org/10.1159/000309775
  20. Farah ME, Costa RA, Muccioli C, et al. Photodynamic therapy with verteporfm for subfoveal choroidal neovascularization in VogtKoyanagi-harada syndrome. Am J Ophthalmol 2002;134:137-9 https://doi.org/10.1016/S0002-9394(02)01456-3
  21. O WH, Yu HG, Jeong H. Photodynamic Therapy with Verteporfin for subfoveal choroidal Neovascularization in Vogt-Koyanagi-Harada syndrome. J Korean Ophthalmol Soc 2004;45:869-74
  22. Boemel G, Ogden TE. Clinical electrophysiology, In : Ryan SJ, ed. Retina, 3rd ed. St. Louis, Mosby, 2001; v. 1. Chap. 16
  23. Marmor MF, Hood DC, Keating D, et al. Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol 2003;106:105-15 https://doi.org/10.1023/A:1022591317907
  24. Stubiger N, Besch D, Deuter CM, et al. Multifocal ERG changes in patients with ocular Behcet's disease during therapy with interferon alpha 2a. Adv Exp Med BioI 2003;528:529-32